Image For Activity Cover
Diabetes with Cardiovascular and Kidney Complications
Learning Objectives
  • Recall current guidelines for the management of people with type 2 diabetes and chronic kidney disease (CKD).
  • Identify options to reduce cardiovascular (CV) risk in people with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).
  • Summarize the evidence supporting the use of sodium–glucose cotransporter 2 (SGLT2) inhibitor treatment for patients with heart failure with reduced ejection fraction (HFrEF).
Faculty
Jennifer B. Green, MD 
Professor of Medicine, Endocrinology, Metabolism, and Nutrition 
Duke University School of Medicine 
Duke Clinical Research Institute 
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
American Diabetes Association 2451 Crystal Drive, Suite 900, Arlington, VA 22202 1-800-DIABETES
Follow us on
Copyright All rights reserved.
Android App Download IOS App Download Powered By